Ultragenyx Pharma (RARE) Misses Q1 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update
May 6, 2020 4:02 PM EDTFirst quarter 2020 total revenue is $36.3 million
First quarter 2020 Crysvita revenue in Ultragenyx territories is $28.8 million
Maintains full year 2020 guidance based on COVID-19 impact to date
NOVATO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended March 31, 2020 and maintained its full year 2020 financial guidance.
The global coronavirus pandemic has... More
